Rocket Companies Inc. Class A Common Stock vs Tempus AI — how do they compare? Rocket Companies Inc. Class A Common Stock trades at $10.66 (market cap $30.67B), while Tempus AI trades at $66.5 (market cap $12.39B). The key difference: Rocket Companies Inc. Class A Common Stock is far larger — about 2.5× Tempus AI's market cap, and Tempus AI is trading nearer its 52-week high, Rocket Companies Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rocket Companies Inc. Class A Common Stock for 0 Days and Tempus AI for 23 Days on average.
| RKT | TEM | |
|---|---|---|
Market Cap | $30.67B | $12.39B |
Volume | 41,104,143 | 4,141,569 |
Sector | Financials | Broad Market / Factor |
52-Week High | $23.44 | $92.45 |
52-Week Low | $10.53 | $41.55 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $60.66B | $13.01B |
Signals from Pluang's Aura AI — not financial advice
Rocket Companies (RKT) trades at $10.83, down 0.37% on the day, with a neutral technical signal and mixed earnings history. The stock is near its 52-week low amid a challenging mortgage market. Recent financials show a net loss of $68 million in 2025 but project a return to profitability in 2026. Analyst consensus is a 'Buy' with a $16.88 price target, though sentiment is tempered by high interest rates and housing market pressures.
Outlook: RKT offers potential upside from current depressed levels if mortgage demand recovers, but faces significant headwinds from persistent high rates and weak housing activity. Risks include competitive pressures and regulatory scrutiny, while opportunities lie in market share gains and cost management improvements. Investors should weigh the cyclical recovery potential against near-term macroeconomic challenges.
Tempus AI (TEM) trades at $68.22, up 0.34% with a bullish technical signal despite negative profitability. The stock shows strong analyst support with 64% buy ratings and a $72.60 consensus target. Recent FDA clearance for ECG-MR AI product and ESMO conference presentations highlight ongoing innovation, while Q2 2026 earnings beat expectations with 22% revenue growth. Cash flow remains positive primarily from financing activities.
While TEM demonstrates strong revenue growth and product innovation, significant risks persist including negative net margins (-17.77%) and substantial insider selling. The stock's high P/B ratio of 27.84 suggests premium valuation despite unprofitability. Near-term catalysts include Q3 earnings and ESMO presentations, but investors should weigh growth potential against persistent losses and competitive pressures in AI healthcare.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Rocket Companies, Inc. operates a homeownership platform spanning mortgage origination and servicing, real estate, title and closing, and personal finance, with flagship brands including Rocket Mortgage, Rocket Close, Rocket Money, Rocket Loans, and Redfin.
Read more on RKT →Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →